For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
|
| Basic information |
| Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
| Yvonne Tsai |
Yipei Hung |
Yipei Hung |
(02)2792-2699 |
5 F., No. 13-20, Sec. 6, Minquan E. Rd., Neihu Dist.,TAIPEI CITY 11494, TAIWAN (R.O.C.) |
2020/12/25 |
| Industrycategory |
Key businesses |
| Biotechnology and Medical Care |
UnicoCell Biomed is a biotechnology company focused on the field of cutting-edged regenerative medicine. We are committed to developing safer and more effective cell therapy products. Our leading cell therapy product “ELIXCYTE;”,an allogeneic “off-the-shelf” stem cell product, has obtained the approval of Investigational New Drug application by TFDA and US-FDA with indication of OA completed phase I/II clinical trial and indication of CKD in the process of phase II clinical trial. We have developed the automated, large-scaled manufacturing technology for ELIXCYTE manufacturing. By this state-of-the-art technology, we will be able to ensure that ELIXCYTE have the best quality and quantity for extensive use.
UnicoCell BioMed also provides the autologous cell processing services for the treatment projects approval by Ministry of Health and Welfare in Taiwan cooperated with medical centers. |
| Financial data |
| Cash flows statement
| Item
|
|
|
| Amount(NTD, in thousands) |
| Cash flows from operating activities |
|
|
| Cash flows from investing activities |
|
|
| Cash flows from financing activities |
|
|
Consolidated/Individual
balance sheet
|
Current assets |
|
|
| Non-current assets |
|
|
| Total assets |
|
|
| Current liabilities |
|
|
| Non-current liabilities |
|
|
| Total liabilities |
|
|
| Share capital |
|
|
| Capital surplus |
|
|
| Retained earnings |
|
|
| Other equity interest |
|
|
| Treasury shares |
|
|
| Total equity attributable to owners of parent |
|
|
| Non-controlling interests |
|
|
| Total equity |
|
|
| Book Value per share(NT$) |
|
|
Consolidated/Individual
profit and loss
statement |
Operating revenue |
|
|
| Operating costs |
|
|
| Gross profit from operations |
|
|
| Operating expenses |
|
|
| Net other income (expenses) |
|
|
| Net operating income |
|
|
| Non-operating income and expenses |
|
|
| Profit before tax |
|
|
| Tax expense |
|
|
| Profit from continuing operations |
|
|
| Profit from discontinued operations |
|
|
| Profit |
|
|
| Other comprehensive income |
|
|
| Comprehensive income |
|
|
| Basic earnings per share |
|
|
 Auditor's report on latest financial statements： auditor's report：
|
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|
